Table 1. HRR gene alterations (deleterious somatic or germline) tested in major trials in mCRPC.

Study	Genes tested	Prevalence
TOPARP-A [5]	BRCA1/2, ATM, FANCA, CHEK2, PALB2	33%
TOPARP-B [20]	BRCA1/2, ATM, CDK12,PALB2, CHEK1,CHEK2, ARID1A, ATRX, FANCA, FANCF,FANCG, FANCI, FANCM, MSH2, NBN, RAD50, WRN	15% (BRCA1/2), 6% (ATM), 28.3% (HRR)
PROFOUND [21]	Cohort A: BRCA1, BRCA2, and ATM Cohort B: BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L	27.9% (HRR)
TRITON 2 [19]	BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD54	NA
TRITON 3 [22]	BRCA1, BRCA2, ATM	25% (HRR)
GALAHAD [23]	BRCA1, BRCA2, ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2	NA

Abbreviations: ARID1A: AT-Rich Interaction Domain 1A; ATM: ataxia-telangiectasia mutated; BRCA: breast cancer gene; BRIP1: BRCA1 Interacting Protein C-terminal Helicase 1; CHEK2: Checkpoint kinase 2; CDK12: cyclin-dependent kinase 12; FANCA: Fanconi anemia complementation group A; FANCL: Fanconi anemia complementation group L; FANCF: Fanconi anemia complementation group F; FANCG: Fanconi anemia complementation group G; FANCI: Fanconi anemia complementation group I; FANCM: Fanconi anemia complementation group M; NA: not available; PALB2: partner and localizer of BRCA2; PPP2R2A: protein phosphatase 2 regulatory subunit B alpha.